News &amp; Updates

Dual therapy with vonoprazan and amoxicillin (VA-dual) for 10 days results in a 90.8-percent eradication rate of Helicobacter pylori (H pylori) and fewer adverse events (AEs) compared with the standard 14-day bismuth-based quadruple therapy (B-quadruple), a study has shown.

Vonoprazan-amoxicillin on par with quadruple therapy for H pylori eradication

09 May 2024

High- vs low-risk T1a EAC tied to more extraesophageal metastases

Patients with high-risk T1a esophageal adenocarcinoma (EAC) undergoing successful endoscopic eradication therapy (EET) appear to have a greater rate of extraesophageal metastases than those with low-risk T1a EAC on long-term follow-up, reports a study.

High- vs low-risk T1a EAC tied to more extraesophageal metastases

Could 15 years be the new 10 for repeat colonoscopy?

Adults who have tested negative for colorectal cancer (CRC) on initial colonoscopy and have no family history of CRC may only need to undergo a repeat screening after 15 years, according to a new Swedish study.

Could 15 years be the new 10 for repeat colonoscopy?

09 May 2024

Olanzapine vs fosaprepitant: Which is better for CINV prevention?

Olanzapine appears to be just as effective as fosaprepitant, a neurokinin-1 receptor antagonist (NK1-RA), in controlling chemotherapy-induced nausea and vomiting (CINV) in patients with gynaecologic malignancies who were receiving carboplatin/paclitaxel chemotherapy every 3 weeks, a prospective study presented at SGO 2024 suggests. However, the former trumps the latter in terms of cost effectiveness.

Olanzapine vs fosaprepitant: Which is better for CINV prevention?

09 May 2024

Hormone therapy effect on BP dictated by estrogen type

In postmenopausal women, hormone therapy (HT) affects blood pressure (BP) differently based on the formulations used, especially the type of estrogen, according to a study.

Hormone therapy effect on BP dictated by estrogen type

More evidence supports enzalutamide’s link with poorer mood and cognitive outcomes in mCRPC

Patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide reported more fatigue, depression and deterioration in perceived cognitive ability, and slower reaction time than those receiving abiraterone acetate, according to results of the ACE study.

More evidence supports enzalutamide’s link with poorer mood and cognitive outcomes in mCRPC

09 May 2024

Rapid, durable responses with nab-sirolimus in gynaecologic or peritoneal PEComa

Treatment with the mammalian target of rapamycin inhibitor nab-sirolimus yields rapid and durable responses among patients with perivascular epithelioid sarcoma (PEComa) of gynaecologic or peritoneal origin in a subgroup analysis of the phase II AMPECT trial.

Rapid, durable responses with nab-sirolimus in gynaecologic or peritoneal PEComa

Full-bladder strategy enhances endometrial sampling experience

Pipelle endometrial sampling with a full bladder reduces initial insertion failure rate and procedure-related pain, thereby increasing patient satisfaction, as compared with the standard process, according to a study.

Full-bladder strategy enhances endometrial sampling experience

Quit rates after failed treatment for smoking cessation improve by upping dosage

08 May 2024 by

For smokers who were not able to quit following initial treatment with varenicline or combined nicotine replacement therapy (CNRT), bumping up their dosages or switching from CNRT to varenicline appears to be an effective rescue strategy, as shown in a study.

Quit rates after failed treatment for smoking cessation improve by upping dosage

AI algorithm boasts accuracy in stone volume determination

An automated artificial intelligence (AI) algorithm demonstrates accuracy and efficiency in determining stone volume using computed tomography (CT) scans, as shown in a study.

AI algorithm boasts accuracy in stone volume determination